Prospective clinical and electrophysiological follow-up on a multiple sclerosis population treated with interferon beta-1 a: a pilot study

Mult Scler. 2007 Apr;13(3):348-56. doi: 10.1177/1352458506070235. Epub 2007 Jan 29.

Abstract

Objective: To analyse transcranial magnetic stimulation (TMS) variables in a prospective six-month follow-up pilot study on patients suffering from relapsing-remitting multiple sclerosis (RRMS), satisfying inclusion criteria for interferon (IFN) beta-1a treatment.

Background: So far, no predictive factors are available as to the course of RRMS treated with IFN beta-1 a.

Design/methods: Fifteen RRMS patients were studied before (month 0 (M0)) and after IFN beta-1a onset (M3, M6). The parameters analysed were motor functional score (mFS), Expanded Disability Status Scale (EDSS), and TMS variables - central motor conduction time (CMCT) and amplitude ratio (AR).

Results: Four of the six patients with no motor signs at inclusion, subsequently showed signs of pyramidal dysfunction. All had abnormal M0_TMS variables. The number of M0_TMS abnormalities per patient was greatest in the group that showed mFS worsening, and was significantly correlated with M6_EDSS. The M0_CMCT was significantly correlated with M6_EDSS. During follow-up, the number of patients with abnormal TMS variables decreased from 12/15 to 4/15, and the total number of abnormalities decreased from 33.3 to 16.7%.

Conclusions: TMS variables might be predictive of disease progression. The improvement observed here in the TMS variables may reflect an improvement in MS patients undergoing IFN beta treatment.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Adult
  • Age of Onset
  • Disability Evaluation
  • Electrophysiology / methods
  • Evoked Potentials, Motor / drug effects
  • Evoked Potentials, Motor / physiology*
  • Follow-Up Studies
  • Humans
  • Interferon beta-1a
  • Interferon-beta / therapeutic use*
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / physiopathology*
  • Persons with Disabilities
  • Pilot Projects
  • Recurrence
  • Reference Values
  • Treatment Outcome

Substances

  • Adjuvants, Immunologic
  • Interferon-beta
  • Interferon beta-1a